Rigel (RIGL) AI Stock Analysis

• Market Cap: $338.33M
• Dividend Yield: N/A
• Average Volume (3M): 202.73K
• Price to Earnings (P/E): 9.1
• Beta (1Y): 2.06
• Revenue Growth: 68.74%
• EPS Growth: N/A
• Country: US
• Employees: 162
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 0.63
• Shares Outstanding: 17,872,433
• 10 Day Avg. Volume: 239,031
• 30 Day Avg. Volume: 202,732
• PEG Ratio: 0.61
• Price to Book (P/B): 6.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.33
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 0.55
• Enterprise Value/Gross Profit: 2.11
• Enterprise Value/Ebitda: 4.45
• 1Y Price Target: $38.73
• Price Target Upside: 104.60% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 72 Outperform
• Price Target: $21.00 ▲(10.94%Upside)

Rigel Pharmaceuticals' strong financial performance, particularly in terms of revenue growth and profitability, is the most significant factor in its overall score. While the technical indicators suggest some bearish trends, the company's low valuation and positive earnings call guidance bolster its investment appeal. Managing high leverage is a key risk that must be addressed to sustain future growth.

Positive Factors

Clinical Trial Results

The ARROW trial concludes with strong efficacy and safety results for GAVRETO, highlighting its potential in treating RET fusion-positive NSCLC.

Financial Performance

Rigel Pharmaceuticals reported higher-than-expected revenue growth, driven by robust sales of Gavreto and Tavalisse.

International Expansion

Approval from the Korean Ministry of Food and Drug Safety for Tavalisse enhances Rigel's presence in the international market.

Negative Factors

Strategic Decisions

Rigel decided not to exercise its opt-in right for ocadusertib under its agreement with Eli Lilly, reflecting internal strategic prioritization.

Rigel Business Overview & Revenue Model

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

How the Company Makes Money

Rigel Pharmaceuticals generates revenue primarily through the sale of its FDA-approved products, such as fostamatinib, which is marketed under the brand name TAVALISSE for the treatment of chronic immune thrombocytopenia (ITP) in adults. The company also earns revenue through collaborative agreements, which may include upfront payments, milestone payments, and royalties from partners who commercialize its products in territories outside the United States. Additionally, Rigel engages in research and development collaborations, where they receive funding or share in the profits from jointly developed therapies. The company's financial performance is supported by its ability to secure strategic partnerships and licensing agreements, which enhance its market reach and provide additional revenue streams.

Rigel Financial Statement Overview

Summary

Rigel's financials show a company improving from past volatility to profitability, with strong revenue growth and excellent profit margins. However, high leverage and past earnings fluctuations present a risk.

Income Statement

Rigel's income statement reflects a strong performance in recent periods, with significant improvements in profitability. The TTM Gross Profit Margin stands at 89.66%, and the Net Profit Margin is 18.31%, showcasing efficient cost management. Revenue growth is robust, with a 13.28% increase from the previous year, indicating a positive trajectory. EBIT and EBITDA margins are also showing healthy improvements. However, the company has experienced periods of negative earnings in the past, which suggests some volatility in its profitability.

Balance Sheet

The balance sheet shows a mixed picture. The Debt-to-Equity Ratio is high, reflecting a leverage risk, but the company has managed to improve its equity position over the TTM. Return on Equity (ROE) is an impressive 200.22%, driven by improved earnings, although this is partly due to a low equity base. The Equity Ratio is only 10.55%, pointing to a significant reliance on debt financing. Overall, while there are positive signs, the high leverage remains a concern.

Cash Flow

Cash flow statements indicate strong operational cash generation, with Operating Cash Flow significantly exceeding Net Income, resulting in a healthy Operating Cash Flow to Net Income Ratio. Free Cash Flow has also shown substantial growth, with a Free Cash Flow Growth Rate of 13.57% in the TTM. The Free Cash Flow to Net Income Ratio is 0.96, showing strong cash conversion from earnings. This robust cash flow performance provides a solid foundation for future growth and debt servicing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	203.08M	179.28M	116.88M	120.24M	149.24M	108.62M
Gross Profit	175.86M	160.63M	109.77M	118.49M	148.15M	107.73M
EBITDA	47.90M	28.51M	-16.98M	-53.87M	-11.29M	-27.68M
Net Income	37.18M	17.48M	-25.09M	-58.57M	-17.91M	-29.74M
Balance Sheet
Total Assets	175.97M	163.98M	117.22M	134.28M	167.33M	110.38M
Cash, Cash Equivalents and Short-Term Investments	77.10M	77.32M	56.93M	58.21M	124.97M	57.33M
Total Debt	61.07M	59.97M	60.58M	41.55M	30.57M	39.09M
Total Liabilities	157.41M	160.69M	145.87M	147.90M	136.95M	76.35M
Stockholders Equity	18.57M	3.29M	-28.64M	-13.62M	30.37M	34.03M
Cash Flow
Free Cash Flow	35.69M	31.43M	-20.74M	-74.21M	5.25M	-53.45M
Operating Cash Flow	35.59M	31.47M	-5.74M	-73.76M	5.88M	-52.19M
Investing Cash Flow	-6.74M	4.13M	-4.30M	72.78M	-80.04M	47.47M
Financing Cash Flow	-8.64M	-11.64M	18.37M	6.55M	62.67M	12.57M

Rigel Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Negative. The current price of 18.93 is below the 20-day moving average (MA) of 19.89, below the 50-day MA of 19.49, and below the 200-day MA of 19.17, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 41.77 is Neutral, neither overbought nor oversold. The STOCH value of 30.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RIGL.

Rigel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	72 Outperform	$338.33M	9.13	531.78%	―	68.74%	―
HRTX	61 Neutral	$328.01M	―	40.36%	―	12.43%	91.67%
TRDA	61 Neutral	$275.92M	8.99	7.22%	―	5.74%	24.45%
RGNX	52 Neutral	$440.40M	―	-47.44%	―	80.70%	46.66%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
IVA	45 Neutral	$434.63M	―	344.74%	―	-47.32%	-26.67%
MREO	43 Neutral	$456.33M	―	-92.00%	―	―	―

Rigel Corporate Events

Rigel Pharmaceuticals Approves Equity Plan Amendment

On May 22, 2025, Rigel Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2018 Equity Incentive Plan, adding 700,000 shares for issuance. The plan became effective immediately upon approval. Additionally, stockholders elected directors to serve until the 2028 Annual Meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2023.

The most recent analyst rating on (RIGL) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.